Nkarta Inc (OQ:NKTX)

May 09, 2024 04:01 pm ET
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter ended March 31, 2024. “Cell therapy has the potential to...
Apr 08, 2024 12:55 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ:
Apr 05, 2024 05:44 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ: NKTX) investors concerning the Company’s possible violations of federal securities laws.
Apr 05, 2024 03:35 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ:
Apr 03, 2024 04:02 pm ET
Nkarta to Participate in Upcoming Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences: Needham Virtual Healthcare ConferenceApril 9, 20241:30 p.m....
Mar 25, 2024 06:30 am ET
Nkarta Announces Pricing of $240 Million Underwritten Offering
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and...
Mar 21, 2024 04:01 pm ET
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2023. “Patients with...
Feb 28, 2024 08:01 am ET
Nkarta to Participate in Upcoming Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in three upcoming investor conferences: Cowen Annual Health Care ConferenceMarch 6, 20249:10 a.m....
Jan 19, 2024 01:41 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Nkarta Inc. (NASDAQ: NKTX)
Levi & Korsinsky announces that it has commenced an investigation of Nkarta, Inc. (NASDAQ: NKTX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:...
Jan 10, 2024 08:31 am ET
Thinking about buying stock in American Lithium, Nkarta, Riot Platforms, Aquestive Therapeutics, or Nvni Group?
NEW YORK, Jan. 10, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMLI, NKTX, RIOT, AQST, and NVNI.
Jan 09, 2024 10:25 am ET
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
FN Media Group News Commentary - According to the report titled "Aging in the United States," published by the Population Reference Bureau, "the number of Americans aged 65 and older is projected to increase more than double over 95 million by the...
Dec 09, 2023 08:31 pm ET
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced a poster presentation at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition...
Nov 11, 2023 08:15 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Nkarta, Inc. (NASDAQ: NKTX) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Nkarta, Inc. (NASDAQ: NKTX) (“Nkarta”) on behalf of the company’s investors. Since June 2023, shares of Nkarta’s common stock have declined in value from a trading price of over $4.50 per share...
Nov 09, 2023 04:02 pm ET
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the third quarter ended September 30, 2023. “Earlier this month, we announced...
Nov 07, 2023 08:02 am ET
Nkarta to Participate at Upcoming Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at two upcoming investor conferences: Stifel Healthcare ConferenceNovember 14, 202310:55 a.m. ET –...
Oct 31, 2023 03:16 am ET
Investor Alert: Abbott Cooper PLLC Announces Investigation into Nkarta, Inc.; Urges Nkarta Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC is investigating Nkarta, Inc. (NASDAQ: NKTX) (“Nkarta” or the “Company”) on behalf of the Company’s investors to determine whether Nkarta’s board of directors (the “Nkarta Board”) has violated fiduciary duties owed to Nkarta...
Oct 26, 2023 09:54 am ET
Investor Alert: Abbott Cooper PLLC Announces Investigation into Nkarta, Inc.; Urges Nkarta Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC is investigating Nkarta, Inc. (NASDAQ: NKTX) (“Nkarta” or the “Company”) on behalf of the Company’s investors to determine whether Nkarta’s board of directors (the “Nkarta Board”) has violated fiduciary duties owed to Nkarta...
Oct 18, 2023 09:31 am ET
Thinking about buying stock in Assembly Biosciences, Olink Holding, Nkarta, Scisparc, or Aurora Mobile?
NEW YORK, Oct. 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASMB, OLK, NKTX, SPRC, and JG.
Oct 17, 2023 11:47 am ET
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory services and will support Nkarta in early development through select sites of the Lupus Clinical Investigators Network (LuCIN) comprised of top academic centers throughout North America.
Oct 17, 2023 07:01 am ET
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to...
Oct 16, 2023 04:01 pm ET
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates...
Oct 13, 2023 10:23 am ET
Investor Alert: Abbott Cooper PLLC Announces Investigation into Nkarta, Inc.; Urges Nkarta Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC is investigating Nkarta, Inc. (NASDAQ: NKTX) (“Nkarta” or the “Company”) on behalf of the Company’s investors to determine whether Nkarta’s board of directors has violated fiduciary duties owed to Nkarta stockholders. Nkarta...
Aug 10, 2023 07:01 am ET
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2023. “Nkarta remains well positioned to...
Aug 03, 2023 08:02 am ET
Nkarta to Participate at Upcoming Investor Conference
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at an upcoming investor conference: Canaccord Genuity 43rd Annual Growth ConferenceAugust 10,...
Jul 05, 2023 04:02 pm ET
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of Alyssa Levin as Chief Financial and Business Officer. “Alyssa is a...
Jun 27, 2023 07:01 am ET
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced positive updated data from its Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r) acute...
Jun 26, 2023 04:01 pm ET
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, June 27, 2023 at 8:00 a.m. ET to review updated clinical data from...
Jun 10, 2023 10:47 am ET
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose in the Phase 1 dose escalation studyData demonstrate potential for redosing of...
May 11, 2023 04:02 pm ET
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter ended March 31, 2023. “Nkarta remains focused on the potential...
May 11, 2023 04:01 pm ET
Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will present preliminary data from its Phase 1 dose escalation clinical trial of NKX019 at two upcoming...
Apr 17, 2023 05:01 pm ET
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and...
Apr 12, 2023 09:06 pm ET
Nkarta to Participate at Upcoming Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences: 22nd Annual Needham Virtual Healthcare...
Mar 30, 2023 04:01 pm ET
Nkarta Announces Departure of Chief Financial & Business Officer
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Nadir Mahmood, PhD, has resigned his position as chief financial and business...
Mar 16, 2023 04:01 pm ET
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2022. “Clinical...
Feb 09, 2023 08:02 am ET
Nkarta to Participate at Upcoming Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences: SVB Securities Global Biopharma...
Jan 09, 2023 04:30 pm ET
Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the promotion of David R. Shook, M.D., to the role of Chief Medical Officer. Dr. Shook...
Dec 05, 2022 07:02 am ET
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)5 CRs achieved across all dose levels after a single cycle (3 weekly doses) of NKX019 monotherapy; 3 partial...
Dec 02, 2022 04:02 pm ET
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, December 5, 2022 at 8:00 a.m. ET to review updated...
Nov 09, 2022 04:02 pm ET
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the third quarter ended September 30, 2022. “The third quarter...
Nov 07, 2022 08:52 am ET
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and...
Nov 02, 2022 08:02 am ET
Nkarta to Participate at Upcoming Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences: Cowen IO Next SummitNovember 11,...
Aug 11, 2022 04:02 pm ET
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the second quarter ended June 30, 2022. “Nkarta’s performance...
Jul 25, 2022 04:31 pm ET
Nkarta Announces Key Senior Leadership Team Appointments
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the promotions of Ralph Brandenberger, PhD, to Chief Technical Officer and Yvonne Li,...
May 31, 2022 07:02 am ET
Nkarta to Participate at Upcoming Investor Conference
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at an upcoming investor conference: Cowen 3rd Annual Oncology Innovation...
May 16, 2022 04:02 pm ET
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of David R. Shook, MD, as Vice President, Clinical Development. Dr....
May 12, 2022 04:02 pm ET
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the first quarter ended March 31, 2022. “Last month marked an...
Apr 28, 2022 04:01 pm ET
Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced the closing of its previously announced underwritten public offering of 13,333,334 shares of its common...
Apr 26, 2022 10:55 am ET
Thinking about buying stock in Agile Therapeutics, Evoke Pharma, Warner Bros Discovery, Nkarta, or Sky Harbour?
NEW YORK, April 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGRX, EVOK, WBD, NKTX, and SKYH.
Apr 25, 2022 11:19 pm ET
Nkarta Announces Pricing of Upsized Public Offering of Common Stock
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price to the...
Apr 25, 2022 04:01 pm ET
Nkarta Announces Proposed Public Offering of Common Stock
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced that it has commenced a proposed underwritten public offering to issue and sell $150 million of shares of...
Apr 25, 2022 08:30 am ET
Thinking about buying stock in ToughBuilt Industries, Ardelyx, Nkarta, Erytech Pharma, or BigBear.ai?
NEW YORK, April 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, ARDX, NKTX, ERYP, and BBAI.
Apr 25, 2022 07:00 am ET
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive preliminary Phase 1 data from independent dose finding studies of its two lead chimeric antigen...
Apr 22, 2022 04:10 pm ET
Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, April 25, 2022 at 8:00 a.m. ET to review clinical data...
Apr 08, 2022 01:25 pm ET
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and...
Apr 08, 2022 07:58 am ET
Nkarta to Participate at Upcoming Investor Conference
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at an upcoming investor conference: 21st Annual Needham Virtual Healthcare...
Mar 29, 2022 08:02 am ET
Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, announced today the appointment of Angela M. Thedinga, MBA, MPH, to its Board of Directors. “The...
Mar 17, 2022 04:02 pm ET
Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2021. “2021 was a...
Mar 08, 2022 04:35 pm ET
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will present four posters at the upcoming American Association for Cancer Research (AACR)...
Feb 10, 2022 08:02 am ET
Nkarta to Participate at Upcoming Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences: SVB Leerink 11th Annual Global Healthcare...
Dec 16, 2021 08:02 am ET
Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation...
Dec 13, 2021 04:02 pm ET
Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today presented a trial in progress poster on NKX019 for the treatment of relapsed and refractory B-cell malignancies...
Nov 12, 2021 07:15 am ET
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and...
Nov 10, 2021 04:01 pm ET
Nkarta Reports Third Quarter 2021 Financial Results and Business Update
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the third quarter ended September 30, 2021. “We are on track to...
Nov 04, 2021 08:04 am ET
Nkarta to Participate at Upcoming Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences: Cowen 5th Annual IO Next SummitNovember...
Oct 07, 2021 04:01 pm ET
Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced NKX019 and NKX101 clinical development program updates. Patients have been dosed in the...
Oct 01, 2021 08:08 am ET
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced four presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and...
Sep 14, 2021 08:32 am ET
Nkarta to Participate at Upcoming Investor Conference
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference: Cantor Virtual Global Healthcare...
Aug 12, 2021 04:02 pm ET
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the second quarter ended June 30, 2021. “Nkarta continues to set the pace for...
Jul 14, 2021 07:00 am ET
Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it has signed a lease agreement for a facility to support research and development and future...
Jun 16, 2021 07:00 am ET
Nkarta to Present at Upcoming Investor Conference
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference: Raymond James Human Health Innovation...
Jun 14, 2021 07:01 am ET
Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Chief Executive Officer Paul Hastings has been elected as the Chair of the Biotechnology...
May 25, 2021 07:30 am ET
Nkarta Announces June 2021 Investor Conference Schedule
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference: Jefferies Virtual Healthcare ConferenceJune...
May 13, 2021 04:02 pm ET
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the first quarter ended March 31, 2021. “As Nkarta prepares NKX019, our...
May 06, 2021 04:01 pm ET
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
Nkarta obtains a license to CRISPR gene editing technology for use in its own engineered NK cell therapy products- -Nkarta to host conference call today at 4:30 p.m. ET- ZUG, Switzerland, CAMBRIDGE, Mass., and SOUTH SAN FRANCISCO, Calif., May 06,...
Apr 28, 2021 08:02 am ET
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND)...
Mar 25, 2021 04:03 pm ET
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2020. “We...
Feb 17, 2021 04:03 pm ET
Nkarta Announces February and March 2021 Investor Conference Schedule
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences: SVB Leerink 10th Annual...
Nov 12, 2020 04:03 pm ET
Nkarta Reports Third Quarter 2020 Financial Results
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the third quarter ended September 30, 2020, and highlighted...
Nov 12, 2020 04:02 pm ET
Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the first patient has been treated in the first-in-human Phase 1 clinical trial...
Nov 09, 2020 08:02 am ET
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced a preclinical update on NKX019, its investigational allogeneic cancer immunotherapy...
Nov 05, 2020 04:02 pm ET
Nkarta Announces November & December 2020 Investor Conference Schedule
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences: Cowen 2020 IO Next...
Oct 05, 2020 04:02 pm ET
Nkarta Announces Leadership Changes
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Nadir Mahmood, Ph.D., Chief Business Officer of Nkarta, is assuming the expanded...
Sep 29, 2020 08:02 am ET
Nkarta Announces October 2020 Investor Conference Schedule
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will participate at the following virtual investor conference: Jefferies...
Sep 08, 2020 04:02 pm ET
Nkarta Announces September 2020 Virtual Investor Conference Schedule
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will participate at the following virtual investor conference: Cantor Virtual...
Aug 20, 2020 04:02 pm ET
Nkarta Reports Second Quarter 2020 Financial Results
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the second quarter ended June 30, 2020, and highlighted recent...
Jul 14, 2020 04:15 pm ET
Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the closing of its initial public offering of 16,100,000 shares of common stock,...
Jul 10, 2020 12:44 am ET
Nkarta Announces Pricing of Initial Public Offering
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the pricing of its initial public offering of 14,000,000 shares of common stock at a...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.